# Evaluation of Symbicort® Turbuhaler® (Budesonide/Formoterol) in Chronic Obstructive Pulmonary Disease (COPD)

> **NCT00837629** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 743 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT00837629
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** 2007-09
- **Final completion:** 2007-09
- **Target enrollment:** 743 (ACTUAL)
- **Last updated:** 2011-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00837629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00837629, "Evaluation of Symbicort® Turbuhaler® (Budesonide/Formoterol) in Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00837629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*